Expert Interview
Discussing the ASCO 2022 poster "A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis" from Karyopharm Therapeutics
Ticker(s): KPTI, INCYInstitution: University of Utah
- Professor in the Division of Hematology and Hematologic Malignancies & Huntsman Cancer Institute Investigator at the University of Utah.
- Member of the Cell Response and Regulation Program and the Imaging, Diagnostics, and Therapeutics Program.
- Research focuses on elucidating the molecular basis of hematological diseases to discover their either somatic or germline underlying mutations and then determine the functions of the mutations.
How many myelofibrosis patients do you treat?
Added By: wilson_adminWhat were your thoughts on the results shown so far?
Added By: wilson_adminWhat are your expectations for the updated results?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
